Table 1.

Select Studies of Intralesional Therapies^a

First Author on Study	Treatment	Documented Bystander Effect	No. of Participants	Dosing	Dosing Interval	Treatment Duration	CR, %	PR, %	SD, %	PD, %
Bedikian16	Velimogene aliplasmid	Yes	127	0.5–2 mg	Once weekly	6 wk	3	9	25	63
Stopeck19	Velimogene aliplasmid	No	51	10 μg	Wk 1–4, 8, 9	≤ 6 cycles	2	16	24	59
Gonzalez27	Velimogene aliplasmid	No	77	10 μg	Once weekly for 6 wk	≤ 3 cycles	3	7	23	68
Karakousis28	BCG	No	8	0.1 mL of 4 × 10″ to 9 × 10″ viable organisms/mL)	NA	Once	75	0	0	25
Kidner41	BCG/Imiquimod	No	19	3 × 106 cfu/5%	5–7 d/wk for every 2 wk	2 injections titrated to local inflammation	56	11	33	0
Marty33	ECT/Bleo	No	41b	≤ 1000 IU/cm3 tumor depending on tumor size	NA	Once	73	11	11	5
	ECT/Cis			≤ 2 mg/cm3 depending on tumor size
Byrne20	ECT/Bleo vs Bleo vs ECT	No	19	1 U/mL tumor volume	4, 8, or 12 wk	4, 8, or 12 wk	72	5	18	5
Heller32	ECT/Bleo vs Bleo vs electroporation	No	34	0.025 U, 1250 V/cm	Once	Once	89	10	1	0
Mir31	ECT/Bleo	No	20	18 or 27 U/m2, 1300 V/cm	Once	Once	53	39	8	0
Ridolfi34	GMCSF, IL-2	No	16	150 ng, 3 million IU	Every 21 d	6 cycles	0	13	69	19
Boyd46	IL-2	No	39	10.4 MIU	Biweekly	4 cycles	51	31	18 (SD/PD)c
Weide18	IL-2	No	48	0.3–6.0 MIU	3 times a wk	1–32 wk	69	NR	NR	NR
Thompson23	10% rose bengal	Yes	80	NA	Wk 1, 8, 12, 16	≤ 4 cycles	26	25	18	31
		Yes	20	NA	Once	1 cycle	20	20	35	25
Senzer38	Talimogene laherparepvec	Yes	50	106 PFU first dose, then 108 PFU thereafter	First interval 3 wk, then every 2 wk	≤ 24	16	10	24	50
Andtbacka39	Talimogene laherparepvec	No	295	106 PFU first dose, then 108 PFU thereafter	First interval 3 wk, then every 2 wk	NR	11	16	73 (SD/PD)c
	GMCSF	No	141	125 μg/m2	Daily × 14 d every 4 wk	NR	1	5	94 (SD/PD)c

^aOnly studies with sufficient data regarding responses are included.

^bMultiple tumor types are included, but responses are not split for study patients with melanoma and without melanoma. Bleo/Cis is equally effective.

^cResponses were not split out.

Bleo = bleomycin, Cis = cisplatin, CR = complete response, ECT = electrochemotherapy, GMCSF = granulocyte macrophage colony-stimulating factor, IL-2 = interleukin 2, NA = not applicable, NR = not reported, PD = progression of disease, PFU = plaque-forming unit, PR = partial response, SD = stable disease.